A Safety-Modified SV40 Tag Developed for Human Cancer Immunotherapy

DSpace/Manakin Repository

A Safety-Modified SV40 Tag Developed for Human Cancer Immunotherapy

Show simple item record

dc.contributor.author Tseng-Rogenski, Stephanie S
dc.contributor.author Escara-Wilke, June F
dc.contributor.author Neeley, Yilin C
dc.contributor.author Imperiale, Michael J
dc.contributor.author Arredouani, Mohamed Simo
dc.contributor.author Sanda, Martin George
dc.date.accessioned 2010-12-22T16:08:20Z
dc.date.issued 2008
dc.identifier.citation Tseng-Rogenski, Stephanie S., Mohamed S. Arredouani, June F. Escara-Wilke, Yilin C. Neeley, Michael J. Imperiale, and Martin G. Sanda. 2008. A safety-modified SV40 Tag developed for human cancer immunotherapy. Drug Design, Development and Therapy 2: 17-24. en_US
dc.identifier.issn 1177-8881 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:4633209
dc.description.abstract Simian virus 40 (SV40)-like DNA sequences have been found in a variety of human tumors, raising the possibility that strategies targeting SV40 may provide a potential avenue for immunotherapy directed against SV40 large T Antigen (Tag)-expressing tumors. We generated a recombinant vaccinia (vac-mTag) expressing mTag and herein assessed the ability of mTag to transform cells and to interact with anti-oncoproteins, as well as screened for the presence of potential HLA-A2.1-restricted epitopes within mTag. We found that transfection of cells with mTag did not lead to their transformation. Also, we demonstrated that mTag protein is degraded rapidly in cells. In addition, our work revealed that mTag did not physically interact with certain anti-oncoproteins. Finally, two potential HLA-A2.1-restricted functional epitopes within mTag sequence were identified. Our results show that mTag lacks the oncogenecity of full-length Tag and harbors potential HLA-A2.1-restricted immunogenic epitopes, hence suggesting the safety of vac-mTag for use in cancer immunotherapy. en_US
dc.language.iso en_US en_US
dc.publisher Dove Medical Press en_US
dc.relation.isversionof http://www.dovepress.com/a-safety-modified-sv40-tag-developed-for-human-cancer-immunotherapy-peer-reviewed-article-DDDT-recommendation1 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761181/pdf/ en_US
dash.license LAA
dc.subject modified SV-40 T antigen en_US
dc.subject recombinant vaccinia en_US
dc.subject cancer immunotherapy en_US
dc.title A Safety-Modified SV40 Tag Developed for Human Cancer Immunotherapy en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Drug Design Development and Therapy en_US
dash.depositing.author Arredouani, Mohamed Simo
dc.date.available 2010-12-22T16:08:20Z
dash.affiliation.other HMS^Surgery- Beth Israel-Deaconess en_US

Files in this item

Files Size Format View
2761181.pdf 4.096Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters